Literature DB >> 22018790

Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.

Joshua Roth1, Dmitriy Minond, Etzer Darout, Qin Liu, Janelle Lauer, Peter Hodder, Gregg B Fields, William R Roush.   

Abstract

Matrix metalloproteinase-13 (MMP-13) has been implicated as the protease responsible for collagen degradation in cartilage during osteoarthritis (OA). Compounds that inhibit the metalloproteinase at the Zn binding site typically lack specificity among MMP family members. Analogs of the low-micromolar lead MMP-13 inhibitor 4, discovered through high-throughput screening, were synthesized to investigate structure-activity relationships in this inhibitor series. Systematic modifications of 4 led to the discovery of MMP-13 inhibitors 20 and 24 which are more selective than 4 against other MMPs. Compound 20 is also approximately fivefold more potent as an MMP-13 inhibitor than the original HTS-derived lead compound 4. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22018790      PMCID: PMC3210410          DOI: 10.1016/j.bmcl.2011.09.077

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  21 in total

1.  SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.

Authors:  Donghong Amy Gao; Zhaoming Xiong; Alexander Heim-Riether; Laura Amodeo; E Michael August; Xianhua Cao; Leonard Ciccarelli; Brandon K Collins; Kyle Harrington; Kathleen Haverty; Melissa Hill-Drzewi; Xiang Li; Shuang Liang; Steluta Mariana Margarit; Neil Moss; Nelamangala Nagaraja; John Proudfoot; Rene Roman; Sabine Schlyer; Lana Smith Keenan; Steven Taylor; Bernd Wellenzohn; Dieter Wiedenmayer; Jun Li; Neil A Farrow
Journal:  Bioorg Med Chem Lett       Date:  2010-07-15       Impact factor: 2.823

2.  Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.

Authors:  Daniel P Becker; Thomas E Barta; Louis J Bedell; Terri L Boehm; Brian R Bond; Jeffery Carroll; Chris P Carron; Gary A Decrescenzo; Alan M Easton; John N Freskos; Chris L Funckes-Shippy; Marcia Heron; Susan Hockerman; Carol Pearcy Howard; James R Kiefer; Madeleine H Li; Karl J Mathis; Joseph J McDonald; Pramod P Mehta; Grace E Munie; Teresa Sunyer; Craig A Swearingen; Clara I Villamil; Dean Welsch; Jennifer M Williams; Ying Yu; Jun Yao
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

Review 3.  Structural bases for substrate and inhibitor recognition by matrix metalloproteinases.

Authors:  Loretta Aureli; Magda Gioia; Ilaria Cerbara; Susanna Monaco; Giovanni Francesco Fasciglione; Stefano Marini; Paolo Ascenzi; Alessandra Topai; Massimo Coletta
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

4.  Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.

Authors:  Alexander Heim-Riether; Steven J Taylor; Shuang Liang; Donghong Amy Gao; Zhaoming Xiong; E Michael August; Brandon K Collins; Bennett T Farmer; Kathleen Haverty; Melissa Hill-Drzewi; Hans-Dieter Junker; S Mariana Margarit; Neil Moss; Thomas Neumann; John R Proudfoot; Lana Smith Keenan; Renate Sekul; Qiang Zhang; Jun Li; Neil A Farrow
Journal:  Bioorg Med Chem Lett       Date:  2009-08-03       Impact factor: 2.823

Review 5.  Matrix metalloproteinase proteomics: substrates, targets, and therapy.

Authors:  Charlotte J Morrison; Georgina S Butler; David Rodríguez; Christopher M Overall
Journal:  Curr Opin Cell Biol       Date:  2009-07-16       Impact factor: 8.382

6.  A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.

Authors:  Vijaykumar M Baragi; Gabriel Becher; Alison M Bendele; Ralf Biesinger; Harald Bluhm; Jürgen Boer; Hongbo Deng; Rory Dodd; Michael Essers; Tim Feuerstein; Brian M Gallagher; Christian Gege; Matthias Hochgürtel; Michael Hofmann; Andreas Jaworski; Lixia Jin; Andrew Kiely; Brian Korniski; Heiko Kroth; Darrell Nix; Bert Nolte; Dorothea Piecha; Timothy S Powers; Frank Richter; Matthias Schneider; Christoph Steeneck; Irving Sucholeiki; Arthur Taveras; Andreas Timmermann; Joshua Van Veldhuizen; Juergen Weik; Xinyuan Wu; Bing Xia
Journal:  Arthritis Rheum       Date:  2009-07

7.  Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.

Authors:  Julian A Blagg; Mark C Noe; Lilli A Wolf-Gouveia; Lawrence A Reiter; Ellen R Laird; Shang-Poa P Chang; Dennis E Danley; James T Downs; Nancy C Elliott; James D Eskra; Richard J Griffiths; Joel R Hardink; Amber I Haugeto; Christopher S Jones; Jennifer L Liras; Lori L Lopresti-Morrow; Peter G Mitchell; Jayvardhan Pandit; Ralph P Robinson; Chakrapani Subramanyam; Marcie L Vaughn-Bowser; Sue A Yocum
Journal:  Bioorg Med Chem Lett       Date:  2005-04-01       Impact factor: 2.823

8.  Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.

Authors:  Mark E Schnute; Patrick M O'Brien; Joe Nahra; Mark Morris; W Howard Roark; Cathleen E Hanau; Peter G Ruminski; Jeffrey A Scholten; Theresa R Fletcher; Bruce C Hamper; Jeffery N Carroll; William C Patt; Huey S Shieh; Brandon Collins; Alexander G Pavlovsky; Katherine E Palmquist; Karl W Aston; Jeffrey Hitchcock; Michael D Rogers; Joseph McDonald; Adam R Johnson; Grace E Munie; Arthur J Wittwer; Chiu-Fai Man; Steven L Settle; Olga Nemirovskiy; Lillian E Vickery; Arun Agawal; Richard D Dyer; Teresa Sunyer
Journal:  Bioorg Med Chem Lett       Date:  2009-11-22       Impact factor: 2.823

9.  High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.

Authors:  Janelle L Lauer-Fields; Dmitriy Minond; Peter S Chase; Pierre E Baillargeon; S Adrian Saldanha; Roma Stawikowska; Peter Hodder; Gregg B Fields
Journal:  Bioorg Med Chem       Date:  2008-03-06       Impact factor: 3.641

10.  Characterization of an exosite binding inhibitor of matrix metalloproteinase 13.

Authors:  Lata T Gooljarsingh; Ami Lakdawala; Frank Coppo; Lusong Luo; Gregg B Fields; Peter J Tummino; Richard R Gontarek
Journal:  Protein Sci       Date:  2007-11-27       Impact factor: 6.725

View more
  16 in total

1.  Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.

Authors:  Roma Stawikowska; Mare Cudic; Marc Giulianotti; Richard A Houghten; Gregg B Fields; Dmitriy Minond
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

2.  Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies.

Authors:  Sabrina Amar; Gregg B Fields
Journal:  Expert Rev Proteomics       Date:  2015-07-15       Impact factor: 3.940

Review 3.  The history of matrix metalloproteinases: milestones, myths, and misperceptions.

Authors:  Rugmani Padmanabhan Iyer; Nicolle L Patterson; Gregg B Fields; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-17       Impact factor: 4.733

4.  Simple pseudo-dipeptides with a P2' glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins.

Authors:  Laurent Devel; Fabrice Beau; Mehdi Amoura; Laura Vera; Evelyne Cassar-Lajeunesse; Sandra Garcia; Bertrand Czarny; Enrico A Stura; Vincent Dive
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

Review 5.  Is there new hope for therapeutic matrix metalloproteinase inhibition?

Authors:  Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Nat Rev Drug Discov       Date:  2014-11-07       Impact factor: 84.694

6.  SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.

Authors:  Anna M Knapinska; Daniela Dreymuller; Andreas Ludwig; Lyndsay Smith; Vladislav Golubkov; Anjum Sohail; Rafael Fridman; Marc Giulianotti; Travis M LaVoi; Richard A Houghten; Gregg B Fields; Dmitriy Minond
Journal:  J Med Chem       Date:  2015-08-04       Impact factor: 7.446

7.  The synthesis and application of Fmoc-Lys(5-Fam) building blocks.

Authors:  Michal Tokmina-Roszyk; Dorota Tokmina-Roszyk; Gregg B Fields
Journal:  Biopolymers       Date:  2013-07       Impact factor: 2.505

8.  Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.

Authors:  Dmitriy Minond; Mare Cudic; Nina Bionda; Marc Giulianotti; Laura Maida; Richard A Houghten; Gregg B Fields
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

9.  Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability.

Authors:  Anna M Knapinska; Chandani Singh; Gary Drotleff; Daniela Blanco; Cedric Chai; Jason Schwab; Anu Herd; Gregg B Fields
Journal:  ChemMedChem       Date:  2021-01-26       Impact factor: 3.466

10.  Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.

Authors:  Rita Fuerst; Jun Yong Choi; Anna M Knapinska; Lyndsay Smith; Michael D Cameron; Claudia Ruiz; Gregg B Fields; William R Roush
Journal:  Bioorg Med Chem       Date:  2018-08-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.